Contributions of the Japanese Gynecologic Oncology Group (JGOG) in Improving the Quality of Life in Women With Gynecological Malignancies

Masayuki Futagami; Yoshihito Yokoyama; Muneaki Shimada; Shinya Sato; Etsuko Miyagi; Akiko Tozawa-Ono; Nao Suzuki; Masaki Fujimura; Yoichi Aoki; Satoru Sagae; Toru Sugiyama

doi:10.1007/s11912-017-0580-y

Contributions of the Japanese Gynecologic Oncology Group (JGOG) in Improving the Quality of Life in Women With Gynecological Malignancies

Masayuki Futagami, Yoshihito Yokoyama, Muneaki Shimada, Shinya Sato, Etsuko Miyagi, Akiko Tozawa-Ono, Nao Suzuki, Masaki Fujimura, Yoichi Aoki, Satoru Sagae, Toru Sugiyama

Obstetrics, Gynecology and Urology

Research output: Contribution to journal › Review article › peer-review

3 Citations (Scopus)

Abstract

The Japanese Gynecologic Oncology Group (JGOG) is leading Japan in the treatment of gynecological malignancies. The JGOG consists of three treatment committees focusing on uterine cervical cancer, endometrial cancer, and ovarian cancer. Each committee makes efforts to improve treatment and diagnosis. In addition, the Supportive and Palliative Care Committee was established in 2015. Novel studies of supportive care and palliative care have been initiated by this committee. Furthermore, surveys about not only treatment results such as overall survival rates but also quality of life (QOL) and cost-effectiveness assessments are performed by the ovarian cancer committee. Improvements of patients’ QOL in the treatment of gynecological malignancies were divided into three concepts as follows: QOL associated with cancer treatment, health care after cancer therapy, and progression of cancer. In this review, we report the contributions and future plans for the improvement of QOL in patients with gynecological malignancies.

Original language	English
Article number	25
Journal	Current Oncology Reports
Volume	19
Issue number	4
DOIs	https://doi.org/10.1007/s11912-017-0580-y
Publication status	Published - 2017 Apr 1

Keywords

Gynecological malignancies
JGOG
QOL
Supportive and Palliative Care Committee

ASJC Scopus subject areas

Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s11912-017-0580-y

Cite this

Contributions of the Japanese Gynecologic Oncology Group (JGOG) in Improving the Quality of Life in Women With Gynecological Malignancies. / Futagami, Masayuki; Yokoyama, Yoshihito; Shimada, Muneaki; Sato, Shinya; Miyagi, Etsuko; Tozawa-Ono, Akiko; Suzuki, Nao; Fujimura, Masaki; Aoki, Yoichi; Sagae, Satoru; Sugiyama, Toru.

In: Current Oncology Reports, Vol. 19, No. 4, 25, 01.04.2017.

Research output: Contribution to journal › Review article › peer-review

Futagami, Masayuki ; Yokoyama, Yoshihito ; Shimada, Muneaki ; Sato, Shinya ; Miyagi, Etsuko ; Tozawa-Ono, Akiko ; Suzuki, Nao ; Fujimura, Masaki ; Aoki, Yoichi ; Sagae, Satoru ; Sugiyama, Toru. / Contributions of the Japanese Gynecologic Oncology Group (JGOG) in Improving the Quality of Life in Women With Gynecological Malignancies. In: Current Oncology Reports. 2017 ; Vol. 19, No. 4.

@article{43ca0db936a84b198b2135883195715f,

title = "Contributions of the Japanese Gynecologic Oncology Group (JGOG) in Improving the Quality of Life in Women With Gynecological Malignancies",

abstract = "The Japanese Gynecologic Oncology Group (JGOG) is leading Japan in the treatment of gynecological malignancies. The JGOG consists of three treatment committees focusing on uterine cervical cancer, endometrial cancer, and ovarian cancer. Each committee makes efforts to improve treatment and diagnosis. In addition, the Supportive and Palliative Care Committee was established in 2015. Novel studies of supportive care and palliative care have been initiated by this committee. Furthermore, surveys about not only treatment results such as overall survival rates but also quality of life (QOL) and cost-effectiveness assessments are performed by the ovarian cancer committee. Improvements of patients{\textquoteright} QOL in the treatment of gynecological malignancies were divided into three concepts as follows: QOL associated with cancer treatment, health care after cancer therapy, and progression of cancer. In this review, we report the contributions and future plans for the improvement of QOL in patients with gynecological malignancies.",

keywords = "Gynecological malignancies, JGOG, QOL, Supportive and Palliative Care Committee",

author = "Masayuki Futagami and Yoshihito Yokoyama and Muneaki Shimada and Shinya Sato and Etsuko Miyagi and Akiko Tozawa-Ono and Nao Suzuki and Masaki Fujimura and Yoichi Aoki and Satoru Sagae and Toru Sugiyama",

note = "Funding Information: Nao Suzuki has received research support through grants from Novartis Pharma K.K., Kyowa Hakko Kirin Co., Ltd., Shionogi & Co., Ltd., Tsumura & Co., Sanofi K.K., Mochida Pharmaceutical Co., Ltd., MSD K.K., Nippon Shinyaku Co., Ltd., Chugai Pharmaceutical Co., Ltd., ASKA Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Factory, Inc., Taiho Pharmaceutical Co., Ltd., Eisai Co., Ltd., Nippon Kayaku Co., Ltd., Kissei Pharmaceutical Co., Ltd., Kaken Pharmaceutical Co., Ltd., CSL Behring K.K., ICREO Co., Ltd., Merck Serono Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Atom Medical Corporation; and has received compensation from Novartis Pharma K.K., Kyowa Hakko Kirin Co., Ltd., Mochida Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., ASKA Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Eisai Co., Ltd., Nippon Kayaku Co., Ltd., Kissei Pharmaceutical Co., Ltd., CSL Behring K.K., Merck Serono Co., Ltd., Takeda Pharmaceutical Co, Ltd., Daiichi Sankyo Co, Ltd., Bayer Yakuhin, Ltd., AstraZeneca K.K., Pfizer Japan Inc., and Ferring Pharmaceuticals Co., Ltd. for service as a consultant. Publisher Copyright: {\textcopyright} 2017, Springer Science+Business Media New York.",

year = "2017",

month = apr,

day = "1",

doi = "10.1007/s11912-017-0580-y",

language = "English",

volume = "19",

journal = "Current Oncology Reports",

issn = "1523-3790",

publisher = "Current Science, Inc.",

number = "4",

}

TY - JOUR

T1 - Contributions of the Japanese Gynecologic Oncology Group (JGOG) in Improving the Quality of Life in Women With Gynecological Malignancies

AU - Futagami, Masayuki

AU - Yokoyama, Yoshihito

AU - Shimada, Muneaki

AU - Sato, Shinya

AU - Miyagi, Etsuko

AU - Tozawa-Ono, Akiko

AU - Suzuki, Nao

AU - Fujimura, Masaki

AU - Aoki, Yoichi

AU - Sagae, Satoru

AU - Sugiyama, Toru

N1 - Funding Information: Nao Suzuki has received research support through grants from Novartis Pharma K.K., Kyowa Hakko Kirin Co., Ltd., Shionogi & Co., Ltd., Tsumura & Co., Sanofi K.K., Mochida Pharmaceutical Co., Ltd., MSD K.K., Nippon Shinyaku Co., Ltd., Chugai Pharmaceutical Co., Ltd., ASKA Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Factory, Inc., Taiho Pharmaceutical Co., Ltd., Eisai Co., Ltd., Nippon Kayaku Co., Ltd., Kissei Pharmaceutical Co., Ltd., Kaken Pharmaceutical Co., Ltd., CSL Behring K.K., ICREO Co., Ltd., Merck Serono Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Atom Medical Corporation; and has received compensation from Novartis Pharma K.K., Kyowa Hakko Kirin Co., Ltd., Mochida Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., ASKA Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Eisai Co., Ltd., Nippon Kayaku Co., Ltd., Kissei Pharmaceutical Co., Ltd., CSL Behring K.K., Merck Serono Co., Ltd., Takeda Pharmaceutical Co, Ltd., Daiichi Sankyo Co, Ltd., Bayer Yakuhin, Ltd., AstraZeneca K.K., Pfizer Japan Inc., and Ferring Pharmaceuticals Co., Ltd. for service as a consultant. Publisher Copyright: © 2017, Springer Science+Business Media New York.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - The Japanese Gynecologic Oncology Group (JGOG) is leading Japan in the treatment of gynecological malignancies. The JGOG consists of three treatment committees focusing on uterine cervical cancer, endometrial cancer, and ovarian cancer. Each committee makes efforts to improve treatment and diagnosis. In addition, the Supportive and Palliative Care Committee was established in 2015. Novel studies of supportive care and palliative care have been initiated by this committee. Furthermore, surveys about not only treatment results such as overall survival rates but also quality of life (QOL) and cost-effectiveness assessments are performed by the ovarian cancer committee. Improvements of patients’ QOL in the treatment of gynecological malignancies were divided into three concepts as follows: QOL associated with cancer treatment, health care after cancer therapy, and progression of cancer. In this review, we report the contributions and future plans for the improvement of QOL in patients with gynecological malignancies.

AB - The Japanese Gynecologic Oncology Group (JGOG) is leading Japan in the treatment of gynecological malignancies. The JGOG consists of three treatment committees focusing on uterine cervical cancer, endometrial cancer, and ovarian cancer. Each committee makes efforts to improve treatment and diagnosis. In addition, the Supportive and Palliative Care Committee was established in 2015. Novel studies of supportive care and palliative care have been initiated by this committee. Furthermore, surveys about not only treatment results such as overall survival rates but also quality of life (QOL) and cost-effectiveness assessments are performed by the ovarian cancer committee. Improvements of patients’ QOL in the treatment of gynecological malignancies were divided into three concepts as follows: QOL associated with cancer treatment, health care after cancer therapy, and progression of cancer. In this review, we report the contributions and future plans for the improvement of QOL in patients with gynecological malignancies.

KW - Gynecological malignancies

KW - JGOG

KW - QOL

KW - Supportive and Palliative Care Committee

UR - http://www.scopus.com/inward/record.url?scp=85015745976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015745976&partnerID=8YFLogxK

U2 - 10.1007/s11912-017-0580-y

DO - 10.1007/s11912-017-0580-y

M3 - Review article

C2 - 28303492

AN - SCOPUS:85015745976

VL - 19

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 4

M1 - 25

ER -

Contributions of the Japanese Gynecologic Oncology Group (JGOG) in Improving the Quality of Life in Women With Gynecological Malignancies

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this